Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP).

Trial Profile

Open-Label, Exploratory Study of the Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP).

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 Aug 2015

At a glance

  • Drugs Tamibarotene (Primary)
  • Indications Tropical spastic paraparesis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Jul 2011 Planned End Date changed from 1 Oct 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top